Ranbaxy Deal Could Make Investors Shy About Indian Pharmas
This article was originally published in PharmAsia News
The pending sale of India's Ranbaxy Laboratories to Japan's Daiichi Sankyo is leading private equity firms to take a second look at investing in Indian drug makers. The firms see the Daiichi move as illustrating the vulnerability of India's pharma industry. One response could be setting more preconditions before making an investment to keep a company from selling soon after the equity firms provide an infusion of funds. In light of the Daiichi-Ranbaxy deal, investors are likely to see the pharmaceutical industry in India as more acquisition-prone than some other industries. (Click here for more
You may also be interested in...
In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.